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Alpha-2 HS glycoprotein in the hypercalcaemia of multiple
myeloma
S.M. Crawford
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Alpha-2 HS Glycoprotein (a2HS) is the human
analogue of bovine G2B glycoprotein and rabbit
a glycoprotein. It is presumed to be secreted in the
liver, and it is known to be taken up by bone,
where it is concentrated 30-300 fold compared with
other plasma proteins (Triffitt et al., 1976). Its
physiological role is unknown although it has
opsonic properties. The plasma level is reduced in
patients with active Paget's disease of bone (Ashton
& Smith, 1980) and it has been suggested that this
is due to adsorption on to newly formed bone.
In this study the serum level of this protein was
measured in patients with multiple myeloma with
normal and elevated serum calcium concentrations.
Sera were obtained from 28 patients with
multiple myeloma and from 4 patients with
hypercalcaemia due to disseminated carcinoma (1
bronchus, 2 breast, 1 unknown primary). The 20
patients with normal serum calcium include 15 who
were receiving chemotherapy for their disease. All
the patients with hypercalcaemia were treated with
intravenous fluids, prednisolone and chemotherapy.
Sera were also obtained from a control population
of 18 students. After collection, sera were stored at
-20°C until required. Serum calcium was measured
by the routine method used by the hospital which
the patient was attending. The value was adjusted
for the serum albumin level by the method of Payne
et al. (1973). Serum alpha-2 HS glycoprotein was
measured by single radial immunodiffusion, using a
modification of Mancini's method (Mancini et al.,
1965), in which uniform thickness of the agarose gel
was obtained by pouring it on to a 10cm square
glass plate supported on a perfectly flat level
surface. Adhesion of the gel to the plate was
ensured by first applying a very thin skin of 2.5%
agarose in water which was dried on to the plate.
The sample volume applied was 5pl. Antiserum
raised in the rabbit and standards were provided by
Behringwerke, Marburg, Germany. The normal
range quoted by that company is 400-850mgl1'.
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The levels of CX2HS in the control group are
compared in Figure 1 with those in patients with
myeloma and hypercalcaemia due to myeloma and
other forms of malignancy. The range of values in
the normal group was 309-854mgl-, median 452.
The range of the myeloma group was 309-
661mgl-, median 427. There was no statistically
significant difference between these groups (Mann
Whitney, U Test). In 2/4 patients with
hypercalcaemia due to disseminated malignancy the
levels were below the range in the control group,
3/4 individuals with hypercalcaemia due to
disseminated malignancy the levels were below the
range in the control group, 3/4 individuals with
hypercalcaemia related to multiple myeloma had
reduced levels (Figure 1). When the combined
group of 8 patients with hypercalcaemia is
compared with the control group the difference is
statistically highly significant (Mann Whitney, U
Test P=0.0001).
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Figure 1 Distribution of serum 02HS in various
groups of patients.
Longitudinal studies on 4 further patients show
the levels of oc2HS tend to fall fairly sharply when
the calcium level rises above normal. Figure 2
shows the variation of serum LX2HS concentrations
related to calcium levels in patients entering the
terminal phase of the disease. The patient
represented in Figure 2(c) was hypercalcaemic at
presentation, but this was corrected and the patient
treated with melphalan and prednisolone. The
remission so obtained was of short duration, and
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Figure 2 Development of serum a2HS and serum calcium in three myeloma patients. (a) Male aged 70-
IgGK-normal creatinine; (b) male aged 61-IgAK-normal creatinine; (c) male aged 64-IgGK-creatinine in
the range of 114-183 jumol 1-' throughout observation period.
his deterioration and death were heralded by the
development of hypercalcaemia. The fourth patient
in whom longitudinal data are available (Figure 3)
had asymptomatic hypercalcaemia until two
months before her death.
These results indicate that whilst patients with
multiple myeloma do not differ from a normal
group in respect of the serum a2HS concentration,
there is a notable fall in this level in the presence of
hypercalcaemia. Wiedermann et al. (1978) reported
that the serum a2HS in IgG myeloma patients was
lower (mean 460+150(s.d.)mgl-1), compared with
controls (mean 690+110mgl-'). They did not
comment on the serum calcium concentration of
their patients. The association of reduced serum
a2HS and hypercalcaemia has not been reported
before. The tendency for for the level of this protein
to fall in malignancy is well documented (Bradley et
al., 1977; Baskies et al., 1980) and has been
associated with impaired delayed hypersensitivity
reactions.
Chemotherapy has been shown to produce a fall
in the a2HS level (Wilson et al., 1977) though the
myeloma patients' active treatment did not appear
to affect the level to the extent that hypercalcaemia
did. This point requires further evaluation. The
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Figure 3 Serum a2HS and serum calcium in a patient
with chronic hypercalcaemia.
present findings suggest, however, that this protein
has a role in calcium metabolism in malignancy. It
has been shown to bind directly to calcium
phosphates (Wilson et al., 1977) and Ashton &
Smith (1980) suggested that the fall in its
concentration seen in patients with active Paget's
disease was due to adsorption of the protein by
newly formed bone, but they found that the rise
which occurred after treatment was too great to be
accounted for solely by reduction in bone
formation.
The finding of a tendency for serum CX2HS
concentrations to be reduced in patients with
myeloma, a condition in which there is bone
destruction but not replacement, suggest that this
hypothesis does not hold, and it is possible that the
increased rate of bone catabolism in Paget's disease
may be responsible for the reduction seen. A
possible mechanism which may explain these
findings is that x2HS is bound to calcium
phosphate salts as they are released from bone
matrix by osteoclastic activity, whether this activity
is related to Paget's disease or a malignant process.
If that is the case, then levels may be reduced in
patients with hyperparathyroidism.
The mechanisms involved in this process are
clearly complex. The fall in CX2HS level was not
necessarily accompanied by a change in the
albumin level, suggesting that reduced hepatic
synthesis is not the prime cause. One of the patients
described here transiently had a very low level of
ca2HS associated with normal serum calcium and
this cannot be explained. A further patient had a
mildly elevated calcium for several months without
symptoms. The a2HS level was normal until the
calcium started to rise rapidly and the patient's
state began to deteriorate. If this observation proves
repeatable, serum oe2HS may prove helpful in the
clinical interpretation of raised serum calcium levels
in such patients. When the physiological role of
Oe2HS is elucidated it may prove to be a useful
marker of bone metabolism in various pathological
states of the skeleton.
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